Logo
x

Search

Subscribe Now

Non-Metastatic Castration-Resistant

Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer

Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer

  • January 30, 2020
Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

  • January 23, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.